Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Receivables: 2023-2024

Historic Receivables for Iovance Biotherapeutics (IOVA) over the last 2 years, with Dec 2024 value amounting to $69.3 million.

  • Iovance Biotherapeutics' Receivables rose 19.71% to $66.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $267.0 million, marking a year-over-year increase of 204.22%. This contributed to the annual value of $69.3 million for FY2024, which is 45820.53% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Receivables of $69.3 million as of FY2024, which was up 45,820.53% from $151,000 recorded in FY2023.
  • Iovance Biotherapeutics' 5-year Receivables high stood at $69.3 million for FY2024, and its period low was $151,000 during FY2023.
  • Over the past 2 years, Iovance Biotherapeutics' median Receivables value was $34.7 million (recorded in 2023), while the average stood at $34.7 million.
  • Data for Iovance Biotherapeutics' Receivables shows a peak YoY surged of 45,820.53% (in 2024) over the last 5 years.
  • Over the past 2 years, Iovance Biotherapeutics' Receivables (Yearly) stood at $151,000 in 2023, then skyrocketed by 45,820.53% to $69.3 million in 2024.